Positive Results for Lipocine in Obesity Study
Biopharmaceutical company, Lipocine Inc. (Nasdaq: LPCN) has announced positive results from a Phase 2 clinical trial evaluating LPCN 2401 for improving body composition by gaining lean mass and reducing fat mass. Lipocine believes that LPCN 2401 has potential as an adjunct therapy to GLP-1/GIP agonists.
Drugs such as Wegovy®, tirzepatide, and Zepbound® are widely used in chronic weight management. The rapid weight loss observed with these medications includes a substantial proportion of lean mass loss, which can lead to higher fat rebound. Lipocine’s Week 36 LPCN 2401 results support its potential for improved body composition in chronic weight management.
Dr. Mahesh Patel, President and CEO of Lipocine, said, “As an adjunct therapy to GLP-1/GIP agonists, we believe LPCN 2401 may improve muscle mass, quality, and functionality while maintaining weight loss and amplifying fat loss. Furthermore LPCN 2401 could help to attenuate collateral fattening and rebound fat/weight “overshoot” associated with discontinuation of GLP-1/GIP agonists. We look forward to meeting with the FDA to discuss the further development of LPCN 2401 as an aid to weight management interventions.”
Approximately 74% of US adults are either obese or overweight. Obesity is a chronic, relapsing health risk defined by excess body fat which increases the risk of death and major comorbidities such as type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, osteoarthritis of the knee, sleep apnea, and some cancers.
About Lipocine
Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for CNS disorders. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs. For more information, please visit www.lipocine.com.
